Development of a subcutaneously implantable bioartificial pancreas (BAP) with immunoisolatory function could have a great impact on the treatment of diabetes mellitus. We have developed an implantable BAP device with an ethylene vinyl alcohol (EVAL) membrane. In the present study, we used basic fibroblast growth factors (bFGF), which was incorporated in a carrier for sustained release, in order to induce neovascularization when the device was implanted subcutaneously. To maintain the vasculature thus formed, a cell infusion port was attached to the BAP device, through which the device was filled with human liver vascular endothelial cell line TMNK-1, and the vasculature could be adequately maintained. Mice were divided into the following three groups. In group 1, a bFGF-free BAP device was implanted subcutaneously. In group 2, a sustained-release bFGF-impregnated BAP device was implanted. In group 3, a sustained-release bFGFimpregnated BAP device was implanted, and 3 × 10 6 TMNK-1 cells were infused into the implanted device every week. Neovascularization induced in the subcutaneous tissue around the implanted BAP device was macroscopically examined and histologically evaluated. In addition, the tissue blood flow was measured using a laser blood flow meter. In mice in group 3, neovascularization was significantly induced and maintained until week 8 postimplantation. It was confirmed by scanning electron microscopy that infused TMNK-1 cells adhered to the inner polyethylene surface of the device. It was demonstrated that the use of bFGF and vascular endothelial TMNK-1 cells induced and maintained adequate vasculature and tissue blood flow surrounding the implantable bag-type BAP device. We believe that the present study will contribute to BAP development for the treatment of diabetes. 893 894 MIKI ET AL.
INTRODUCTION
cells are allowed to pass, while no cells, antibodies, or complements involved in immune response can pass. Because insulin-secreting cells within the device are Pancreatic islet transplantation can free diabetic patients from insulin injection, although the use of immu-protected from the host's immune system, the use of immunosuppressants is not required. By adjusting the nosuppressive agents is necessary. The long-term use of immunosuppressants puts patients at higher risk of bone pore size of the semipermeable membrane, we can prevent the outflow of proteins. Because xenogeneic or cul-marrow suppression and susceptibility to infections and cancers. As an effective means to solve this problem, a tured cells can be used as a cell source for BAP, the donor shortage, which is a serious problem for trans-bioartificial pancreas (BAP) has been highlighted in recent years (16, 20) . Insulin-secreting cells are filled in a plantation, can be solved (1, 14, 22, 44) . For the development of BAP, many studies have been BAP device with a semipermeable membrane, through which oxygen and nutrients necessary for viability of performed to determine the optimum material, shape, and implantation site for BAP devices (2, 3, (7) (8) (9) (10) (11) 13 ,17-and were thus within the guidelines for the humane care of laboratory animals. 19,23, 25, 40, 45 ). An implantation site for a BAP device needs to be selected so that the device can be easily
The abdomen of each male Balb/C mouse (8-10 weeks of age) was transversely incised under inhalation implanted and if an adverse event occurs can be immediately removed. Therefore, the subcutaneous tissue is anesthesia with sevoflurane (Maruishi Pharmaceutical Co., Osaka, Japan) to produce a 20 × 20-mm subcutane-preferable to the intraperitoneal cavity as the implantation site for a BAP device. Because cells filled in a de-ous pocket. The test animals were divided into the following three groups: group 1-mice implanted with a vice are supplied with oxygen and nutrients diffused from vessels outside of the semipermeable membrane, (bFGF-free) BAP device only (n = 30); group 2-mice implanted with a bFGF-impregnated BAP device only abundant blood flow is required to nourish the filled cells. As subcutaneous tissue is sparsely vascularized, (n = 30); group 3-mice infused with immortalized human vascular endothelial cells (TMNK-1 cells) after im-the cells filled in the device have a limited supply of oxygen and nutrients and a limited removal of wastes plantation of a bFGF-impregnated BAP device (n = 30). For mice in groups 2 and 3, the inner and outer sur- (4, 32, 34, 35) .
It is thus difficult to achieve a sustained viability of faces of the device were coated with 2 mg of microspheres of gelatinized bFGF (100 µl). The BAP device cells filled in the device (5) . So it is necessary to improve the hemodynamic environment surrounding the was implanted in the subcutaneous pocket to ensure that the cell infusion port was oriented cephalad. A 5-0 BAP device by inducing sufficient angiogenesis in the subcutaneous tissue around the device. Although basic Vicryl suture (Ethicon Inc.) was used to close the surgical wound. For mice in group 3, TMNK-1 cells were fibroblast growth factor (bFGF) is frequently used for this purpose (33) , the neovascularization-inducing effect infused into the implanted BAP device 7, 14, 21, 28, 35, 42, and 49 days after subcutaneous implantation. For of bFGF wanes as its concentration decreases, even if a sustained-release property is given to it (41) . each infusion, 3 × 10 6 TMNK-1 cells were suspended in 0.3 ml of phosphate-buffered saline (PBS) and infused For long-term maintenance of the vasculature induced around the BAP device, we considered a signal via the infusion port using a 1-ml syringe and a 21gauge needle. After implantation of the device, the skin from viable cells to be necessary and thus performed this study. Specifically, the surface of a BAP device was was peeled off every week to make a 10 × 10-mm skin flap, and the extent of neovascularization in the flap was coated with gelatinized bFGF, with which neovascularization was induced in the subcutaneous tissue in which observed from the muscle side using a digital camera (CAMEDIA C-4040, Olympus, Tokyo, Japan). the device was implanted. Then human vascular endothelial cells were filled in the implanted BAP device to Quantification of Neovascularization maintain the vasculature thus induced. We obtained fa-After implantation of the device, three mice in each vorable results as anticipated, and hereby report the group were sacrificed every week until week 8 to excise results.
the subcutaneous tissue with the device in it. The tissue MATERIALS AND METHODS samples were preserved in paraformaldehyde for 24 h for paraffin fixation. They were then stained with hema-Preparation of a BAP Device toxylin and eosin (H&E). Viewing the sample under A BAP device (kindly provided by Kuraray Medical 400× magnification using a light microscope, 10 fields Co. Ltd., Tokyo, Japan) with a port for cell infusion was of view of the tissue around the device were randomly prepared to fill cells or retrieve filled cells at any time.
selected, and the number of newly formed vessels was The inner, intermediate, and outer layers of the device counted. were made of polyethylene (20 × 40 mm), EVAL membrane (20 × 40 mm), and polyethylene (20 × 40 mm), Scanning Electron Microscopy (SEM) respectively. A sheet of EVAL membrane was placed Mice were sacrificed at week 8 to remove the imover a sheet of polyethylene, and a sheet of polyethylene planted BAP device. The device was then soaked in a was then placed over the former sheets. They were then 2% glutaraldehyde solution for 2 h, washed three times heat sealed on all four sides (seal width about 3 mm) with a PB solution, allowed to stand in a 2% osmium and cut using a punch. A port for cell infusion (Kawasolution for 2 h, and washed three times with PBS. The sumi Laboratories, Inc., Tokyo, Japan) was attached and sample was then dehydrated with an ethanol solution, adhered to it using polyurethane. The device was sterifreeze-dried with t-butyl alcohol, and observed by SEM. lized with ethylene oxide gas.
Subcutaneous Blood Flow at the Implantation Site Animal Experiments of the BAP Device
Mice were placed in a prone position under inhala-All procedures performed on animals were approved by the Institutional Animal Care and Use Committee tion anesthesia, and the volume of subcutaneous blood flow at the implantation site of the BAP device was in the subcutaneous tissue at the implantation site of the BAP device. The number of newly formed vessels measured and expressed as PU every week until week 8 using a Laser Flowgraphy (SoftCare, Fukuoka, Japan), peaked at week 2 and gradually decreased thereafter in mice in groups 1 and 2. In mice in group 3, on the other according to the manufacturer's protocol.
hand, a significantly larger number of vessels was main-Statistical Analyses tained than in group 1 or 2 ( Fig. 3 ). More specifically, the numbers of newly formed vessels per field at day 7 Mean values are presented with SDs. A Student's ttest was used to calculate the significance of difference were 3.4 ± 1.6, 7.4 ± 1.3, and 7.6 ± 1.4 in groups 1, 2, and 3, respectively. The corresponding numbers at day in mean values. A value of p < 0.05 was considered statistically significant. 14 were 7.8 ± 2.1, 11.4 ± 1.2, and 14.7 ± 1.7. The corresponding numbers at day 56 were 4.4 ± 1.1, 4.4 ± 1.7,
RESULTS
and 11.7 ± 1.8.
Macroscopic Findings of Neovascularization
Immunostaining of Newly Formed Vessels With CD-31 After implantation of the BAP device, the skin was and α-SMA periodically incised open, making a skin flap to macro-
The subcutaneous tissue, into which the BAP device scopically observe neovascularization in the subcutanehad been implanted, was immunostained at week 8 with ous tissue. All mice in group 3 (device + bFGF + TMNK CD-31 as a marker for vascular endothelial cells and αcells) were found to have formed a network of newly SMA as a marker for vascular smooth muscle cells. In formed vessels in the tissue around the BAP device ( Fig.  group 3 , newly formed vessels with a tubular structure 1CC), while no animals in group 1 (device only) had were well stained with both CD-31 ( Fig. 4A ) and αsuch neovascularization (Fig. 1A ). Mice in group 2 (de-SMA ( Fig. 4B ). In group 1, no such stained vessels were vice + bFGF) ( Fig. 1B ) had a network of newly formed observed. In group 2, the vessels were less intensely vessels that was less dense than that in group 3.
stained with CD-31 or α-SMA than those in group 3.
Histological Findings of Neovascularization SEM Observation Histological examination revealed that in mice in
The degree of adhesion of TMNK-1 cells infused in group 3, angiogenesis was markedly induced, resulting the bag was observed by SEM at week 8 after implantain a dense vascular network, and the vasculature was tion of the BAP device. In group 3, the transplanted maintained histologically at week 8 after implantation TMNK-1 cells were well adhered onto the unwoven of the BAP device. On the other hand, no findings of cloth in the bag, and some blood vessel-like structures neovascularization were found in any mice in group 1.
were observed ( Fig. 5 ). On the other hand, no findings Neovascularization was observed in mice in group 2, but of cell adhesion were observed in groups 1 or 2. was less intense than in group 3 (Fig. 2) .
Measurement of Tissue Blood Flow With a Laser Quantification of Neovascularization Blood Flow Meter
Laser blood flow imaging revealed a macroscopically Histological examination was performed using a microscope to count the number of newly formed vessels abundant tissue blood flow visualized as red spots in the Figure 1 , there were many newly formed vessels with a tubular structure in group 3. The tubular structure was found to be full of red blood cells. Many vessels were still observed at week 8 after implantation of the BAP device. In group 1, there were very few newly formed vessels. In group 2, some newly formed vessels were observed, but they were less dense than those in group 3 (original magnification 100×).
tissue sample taken from mice in group 3 at week 4 after day 42, 25.5 ± 0.9; day 49, 23.2 ± 0.8; and day 56, 22.4 ± 1.2. implantation of the BAP device ( Fig. 6 ). In group 1, the color of the tissue image was blue to green, indicating DISCUSSION that the tissue blood flow was scarce (Fig. 6A) . The color tone of the tissue image for group 2 was between It is difficult to control chronic complications of diabetes, including retinopathy, neuropathy, nephropathy, those for groups 1 and 3 (Fig. 6B ). Quantification of the tissue blood flow revealed that group 3 had the highest and vascular complications with the conventional insulin therapy (42) . In 2000, researchers at the University of value, and that the value remained high until week 8, at least, after implantation of the BAP device (Fig. 7) . In Alberta (Canada) reported that 7 of 7 patients who received an islet transplant became independent of insulin contrast, the tissue blood flow in groups 1 and 2 peaked at week 2 and decreased thereafter (Fig. 7) . The blood (36) . Since the success of the Edmonton Protocol, islet transplantation has been an option for the treatment of flow index for group 1 at each time point was as follows: day 0, 9.5 ± 0.6; day 7, 17.0 ± 1.1; day 14, 20.1 ± type 1 diabetes. Because the recipient of an islet transplant can have adequate, timely secretion of insulin ac-1.3; day 21, 10.8 ± 1.2; day 28, 10.8 ± 1.6; day 35, 10.4 ± 1.6; day 42, 10.2 ± 1.3; day 49, 9.7 ± 0.6; and day 56, cording to the blood glucose level, islet transplantation has been expected to become an ideal modality in place 9.5 ± 0.9. The blood flow index for group 2 at each time point was as follows: day 0, 10.8 ± 1.4; day 7, 17.8 ± of insulin therapy (29) . Islet transplantation is considered to be more useful than pancreas transplantation be-1.1; day 14, 24.9 ± 1.2; day 21, 24.0 ± 1.7; day 28, 16.4 ± 1.1; day 35, 13.7 ± 1.4; day 42, 12.9 ± 1.5; day cause it is less invasive and can be easily performed. However, the transplant recipients must be treated with 49, 12.3 ± 1.2; and day 56, 11.9 ± 1.2. The blood flow index for group 3 at each time point was as follows: day immunosuppressive agents for a long period of time. So far, many researchers have been engaged in BAP devel-0, 17.8 ± 1.1; day 7, 17.8 ± 1.3; day 14, 28.4 ± 1.6; day 21, 25.5 ± 1.5; day 28, 26.9 ± 1.5; day 35, 21.3 ± 1.6; opment to solve this problem (22, 24) . The following Histological examination of the subcutaneous tissue at the implantation site of the BAP device revealed that the density of newly formed vessels was the highest in group 3, and that the vessels remained intact at week 8 after implantation of the BAP device (Fig. 2) . The number of vessels per field was histologically determined for each group. In groups 1 and 2, the number of vessels peaked at week 2 after implantation and decreased thereafter. In group 3, on the other hand, the newly formed vessels did not decrease in number and remained intact. three types of BAP device have so far been developed: oping an implantable, bag-type BAP device with a cell infusion port so that we can infuse or retrieve cells at blood reflux-type, microcapsule-type, and macrocapsule-type devices (21, 28, 39) . From a perspective of any time. We decided to implant this device beneath the skin, where it can be easily implanted under local anes-practical use, the device should be designed to make it easily prepared, easily implanted, and easily removed in thesia and easily removed if a problem occurs. There is one big issue, however, with implanting the case of emergency. So we have been engaged in devel- Figure 6 . Evaluation of angiogenesis by laser Doppler tissue blood flow imager. Laser blood flow imaging revealed abundant tissue blood flow visualized as red spots in group 3 even at week 8 after implantation of the BAP device (C). In group 1, on the other hand, the color of the blood flow image was blue to green, indicating a poor tissue blood flow (A). (B) The color tone of the tissue image for group 2 was between those of groups 3 and 1, indicating that the tissue blood flow was insufficient. 1 cells, newly formed vessels induced by bFGF receive a (+) signal directing them to keep the level of growth factors and the vasculature intact. In a sense, we intend to make possible the survival of insulin-secreting cells or islets inoculated in the BAP device by maintaining the newly formed vasculature with the use of TMNK-1 cells.
In the present study, we used a noncontact laser Doppler blood flow meter to enable technically easy, minimally invasive, real-time measurement of neovascularization developed around the BAP device (31) . As expected, we could measure very easily and effectively the tissue blood flow around the BAP device. In addition, the measurements were consistent with histological findings. In both groups 1 and 2, in which TMNK-1 cells were not filled in the BAP device, the number of vessels and the volume of blood flow increased until week 2 after implantation but decreased thereafter. In group 3, in which TMNK-1 cells were filled, the number of newly formed vessels and the volume of blood flow in the subcutaneous tissue were sustained at high levels until week 8. It appeared that newly formed vessels could be sustained as a result of release of growth factors such as VEGF from TMNK-1 cells taking root infused. Although the cells transplanted were humanderived cells with antigenicity different from that of the host animal, SEM revealed that the infused TMNK-1 BAP device in the subcutaneous tissue. Because the subcutaneous tissue has a low density of blood vessels, the cells adhered within the device, indicating that the EVAL membrane functioned properly as an immunoiso-delivery of oxygen and nutrients to cells filled in the BAP device may become insufficient, and the filled cells latory membrane. As cell sources of BAP in place of human adult islet beta cells, the possibilities of ES cells, can neither survive nor perform their function soon after transplantation. To solve this problem, researchers have tissue stem cells, etc., are being vigorously explored (12,37,38). We have also dedicated ourselves to prepare studied the possibility of inducing angiogenesis in the subcutaneous tissue with the use of VEGF or bFGF at human-derived insulin-secreting cells (27) . In 2005, we attempted to materialize the reversible immortalization the time of implantation of the device there (43) . Beta cells, which occupy only a few percent of the capacity of human pancreatic beta cells and succeeded in production of human islet beta cell line for the first time in the of the pancreas, are supplied with about 10% of blood flow passing through the entire pancreas. This fact sug-world (26). It is an important future project to develop a BAP device incorporating artificially generated beta gests that an abundant blood flow is required for timely secretion of insulin by beta cells according to the blood cells and functioning properly for a long period of time.
After neovascularization around the BAP device was in-glucose level (6) . However, the use of blood vessel growth factors such as VEGF and bFGF is not enough duced by sustained-release of bFGF, we filled vascular endothelial cells (TMNK-1 cells) in the device and to sustain angiogenesis-inducing effects (30) . We decided to infuse vascular endothelial cells (TMNK-1 could effectively maintain the vasculature even after the angiogenesis-inducing effect of bFGF was attenuated. cells) in the BAP device, in addition to the use of sustained-release bFGF. We considered that from TMNK-
We are now planning to investigate the therapeutic ef- 
